ArticleAnnals of surgical oncology2025
Prognostic Impact of the Pathologic Response of Patients with Hepatocellular Carcinoma After Preoperative Treatments.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and efficacy of salvage surgery for unresectable hepatocellular carcinoma after conversion with triple therapy: a systematic review and meta-analysis of data from Chinese patients.World journal of surgical oncology · 2025Pooled it
- Neutrophil extracellular traps predict poor response and prognosis in non-small cell lung cancer immunotherapy.Therapeutic advances in medical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) exhibits varying degrees of tumor regression after preoperative treatments. However, the relationship between a tumor residual and its impact on recurrence-free survival (RFS) remains poorly defined. This study aimed to assess the effect of pathologic response on RFS in HCC patients undergoing preoperative treatments.
methodsData from 400 patients with HCC who received preoperative treatments were retrospectively analyzed. The correlation between tumor residual and RFS was assessed using the "surv_cutpoint" function in R software and further validated through Cox proportional hazards regression models, with the objective of identifying a cutoff value that was significantly associated with RFS.
resultsThe overall analysis showed that pathologic response significantly influenced postoperative recurrence when tumor residual of 15% or less was detected. Multivariate regression analysis found that the independent risk factors for RFS were pathologic satellite nodules (hazard ratio [HR], 1.56; 95% confidence interval [CI] 1.05-2.25; P = 0.047), microvascular invasion (HR, 1.72; 95% CI 1.16-2.55; P = 0007), and advanced tumor stage (HR, 1.60; 95% CI 1.05-2.44; P = 0.031). In contrast, an independent protective factor affecting RFS was found to be residual of 15% or less (HR 0.41; 95% CI 0.26-0.63; P < 0.001). Subgroup analyses showed that RFS was significantly associated with a tumor residual cutoff value of 15% in Barcelona Clinic Liver Cancer (BCLC) stage A, 20% in stage BCLC stage B, and 26% in stage BCLC stage C.
conclusionsThis study demonstrated that achieving tumor residual of 15% or less after liver resection significantly reduces postoperative recurrence rates for HCC patients treated with preoperative therapies. The effect of tumor regression on RFS varied according to tumor stages.
Indexed as
Identifiers
40382454What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.